The company's offering of 3.36 million units at $6.125 per unit — each consisting of one share of common stock and one warrant — is expected to close Aug. 23.
The company plans to offer nearly 2.5 million units at a price of $6.00 to $7.00 per unit, which at the midpoint of the range would raise about $16 million.
In 2017, Bionano had $9.5 million in revenues and a net loss of 23.4 million, or $7.66 per share.
With its Direct Labeling and Staining (DLS) chemistry, currently available to early-access users, Bionano is pushing forward with more contiguous genome maps.
At PAG, researchers from the Rockefeller University Vertebrate Genome Laboratory outlined sequencing and assembly strategies for phase 1 of the VGP G10K.
After more than two years of development, the British vendor has matched HPC for sequencing alignment accuracy, at far lower power consumption.
The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.
Increasingly, researchers are combining sequencing, mapping, and scaffolding technologies to generate more contiguous and accurate reference genomes.
The public-private consortium, led by the National Institute of Standards and Technology, recently released four new reference materials.
In PLOS this week: gene expression differences in plants susceptible to or resistant to Plum pox virus, novel human pegivirus, and more.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.